Advanced search

Advanced search in people

Items from 1 to 20 out of 147 results

article

Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome

Anna Koumarianou, Kosmas Daskalakis, Marina Tsoli, Gregory Kaltsas, more

Journal of Neuroendocrinology > 34 > 7 > n/a - n/a

This review reports on the currently available medical treatment options for the control of symptoms due to carcinoid syndrome in patients with neuroendocrine tumors. The efficacy and adverse events (AEs) of approved drugs such as somatostatin analogues (SSA), telotristat ethyl (TE) and interferon‐alpha, are reviewed. Somatostatin analogues remain the standard treatment of carcinoid syndrome based...

article

Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series

David L. Chan, Nick Pavlakis, Megan Crumbaker, Ben Lawrence, more

Asia‐Pacific Journal of Clinical Oncology > 18 > 3 > 209 - 216

Aim Carcinoid heart disease (CHD) is a well‐documented complication of neuroendocrine tumors (NETs) due to secreted hormones causing fibrosis. Somatostatin analogues (SSAs) can decrease hormonal secretion and inhibit tumor growth. The reported incidence of CHD has decreased as SSA use has increased. We describe a series of patients who have developed CHD even though they were treated with SSA therapy...

article

The effects of somatostatin analogues on glycaemia in the treatment of neuroendocrine tumours

Kishen Rajan Patel, Ananda Nahar, Yasir S. Elhassan, Shishir Shetty, more

Journal of Neuroendocrinology > 34 > 4 > n/a - n/a

Long‐acting somatostatin analogues (SSAs) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) because of their ability to control symptoms and prolong survival. SSA use is associated with changes in glucose metabolism. However, the impacts on glycaemic control and body mass index (BMI) caused by SSAs in NETs are largely unknown. In the present study, we evaluated the...

article

Resistance to first‐generation somatostatin receptor ligands does not impair the results of gamma knife radiosurgery in acromegaly

Marco Losa, Eugenia Resmini, Lina R. Barzaghi, Luigi Albano, more

Clinical Endocrinology > 95 > 6 > 849 - 855

Objective Gamma knife radiosurgery (GKRS) has proven to be an effective adjuvant treatment for patients with acromegaly. We performed the present study to investigate, which would be the outcome of GKRS, independently on the response to somatostatin receptor ligand (SRL). Design Retrospective, observational study. Patients Ninety‐six patients with active acromegaly were included. Measurements...

article

The Binding Ability of a Bicyclic Somatostatin Analogue Towards Cu(II) Ions

Aleksandra Marciniak, Weronika Witak, Aleksandra Pieniężna, Justyna Brasuń

Chemistry & Biodiversity > 17 > 8 > n/a - n/a

Somatostatin (SST) analogues have aroused the interest of scientists for years. This group of compounds is used in the diagnosis and treatment of neuroendocrine tumors. However, new molecules useful as radiopharmaceuticals in targeted therapy are still searched for. Bicyclic peptides seem to be very interesting in this context. These molecules are associated with beneficial properties. In this work,...

article

Management of portal hypertension and ascites in polycystic liver disease

Lucas H. P. Bernts, Joost P. H. Drenth, Eric T. T. L. Tjwa

Liver International > 39 > 11 > 2024 - 2033

Patients suffering from polycystic liver disease may develop Hepatic Venous Outflow Obstruction, Portal Vein Obstruction and/or Inferior Caval Vein Syndrome because of cystic mass effect. This can cause portal hypertension, leading to ascites, variceal haemorrhage or splenomegaly. For this review, we evaluate the evidence to provide clinical guidance for physicians faced with this complication. Diagnosis...

article

Phäochromozytom und Paragangliom

W. G. Kunz, C. J. Auernhammer, S. Nölting, T. Pfluger, more

Der Radiologe > 2019 > 59 > 11 > 975-981

Klinischer Hintergrund Bei der laborchemischen Diagnose des Phäochromozytoms (PC) bzw. Paraganglioms (PGL) ist die Lokalisationsdiagnostik für das weitere Management entscheidend. Das PC/PGL kann neben pathognomonischen hormonellen Befunden auch typische Merkmale in der Bildgebung zeigen. Morphologisch lässt es sich jedoch häufig nicht sicher von anderen Pathologien differenzieren. Radiologische...

article

Production and characterization of no-carrier-added ¹⁶¹Tb as an alternative to the clinically-applied ¹⁷⁷Lu for radionuclide therapy

Nadezda Gracheva, Cristina Müller, Zeynep Talip, Stephan Heinitz, more

EJNMMI Radiopharmacy and Chemistry > 2019 > 4 > 1 > 1-16

Background ¹⁶¹Tb is an interesting radionuclide for cancer treatment, showing similar decay characteristics and chemical behavior to clinically-employed ¹⁷⁷Lu. The therapeutic effect of ¹⁶¹Tb, however, may be enhanced due to the co-emission of a larger number of conversion and Auger electrons as compared to ¹⁷⁷Lu. The aim of this study was to produce ¹⁶¹Tb from enriched ¹⁶⁰Gd targets in quantity and...

article

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma

David Taïeb, Rodney J. Hicks, Elif Hindié, Benjamin A. Guillet, more

European Journal of Nuclear Medicine and Molecular Imaging > 2019 > 46 > 10 > 2112-2137

Purpose Diverse radionuclide imaging techniques are available for the diagnosis, staging, and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to detect and localise the disease, these imaging approaches variably characterise these tumours at the cellular and molecular levels and can guide therapy. Here we present updated guidelines jointly approved by the EANM and SNMMI...

article

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

Rosario Pivonello, Giorgio Arnaldi, Carla Scaroni, Carla Giordano, more

Endocrine > 2019 > 64 > 3 > 657-672

A phase III study has demonstrated that 6-month pasireotide treatment induced disease control with good safety in 15–26% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the 6-month efficacy and safety of pasireotide treatment according to the real-world evidence. Thirty-two CD patients started pasireotide at the dose of 600 µg twice a day (bid) and with the chance...

article

Mixed neuroendocrine-non-neuroendocrine carcinoma of gallbladder: case report

Adam Skalický, Lucie Vištejnová, Magdaléna Dubová, Tomáš Malkus, more

World Journal of Surgical Oncology > 2019 > 17 > 1 > 1-6

Background Mixed neuroendocrine-non-neuroendocrine tumors (MINEN) of the gallbladder are extremely rare; indeed, the English expert literature reports a mere handful of case reports and case series on this topic. According to the WHO classification of 2010, MINEN are considered to be tumors consisting of two major components, neuroendocrine and non-neuroendocrine, each of which hosts at least 30%...

article

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

Antongiulio Faggiano, Silvana Di Maio, Carmela Mocerino, Margaret Ottaviano, more

Endocrine > 2019 > 66 > 2 > 417-424

Purpose Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the main therapeutic sequences in G1−G2 NET. Methods A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in...

article

My burning issues in neuroendocrine tumours (NET)

Barbara Kiesewetter, Markus Raderer

memo - Magazine of European Medical Oncology > 2018 > 11 > 4 > 313-316

Summary Several compounds have recently been approved for the systemic treatment of advanced well-differentiated neuroendocrine tumours (NET) of gastroenteropancreatic (GEP) or lung origin. Based on the PROMID and CLARINET trials, somatostatin analogues (SSA) are the preferred first-line approach for all GEP-NET and offer—in addition to antiproliferative effects—durable symptomatic relief for hormonally...

article

Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts

Christian Fottner, Matthias Weber

Wiener klinisches Magazin > 2018 > 21 > 6 > 250-259

Hintergrund Neuroendokrine Neoplasien (NEN) des Verdauungstrakts stellen eine seltene und heterogene Gruppe von Tumorerkrankungen dar. Dies erschwert die Vorgabe einheitlicher Therapieschemata. Ziel Die aktuelle Datenlage zur medikamentösen Therapie gastrointestinaler NEN soll dargestellt werden. Methoden Diskussion publizierter Studien und Expertenempfehlungen zur medikamentösen Therapie von...

article

Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE)

Gerardo Nardone, Debora Compare, Alberto Martino, Alba Rocco

Digestive and Liver Disease > 2018 > 50 > 6 > 542-548

Angioectasias (AD) belong to benign vascular malformations of the gastrointestinal tract and are responsible for about 4–7% of upper non variceal bleeding, 30–40% of small bowel occult bleeding and 3–40% of colonic bleeding episodes. Gastrointestinal haemorrhage secondary to AD represents an important diagnostic and therapeutic problem that negatively impacts on the quality of life of patients and...

article

Anti-inflammatory Effect of Somatostatin Analogue Octreotide on Rheumatoid Arthritis Synoviocytes

Claudia Casnici, Donatella Lattuada, Katia Crotta, Marcello Claudio Truzzi, more

Inflammation > 2018 > 41 > 5 > 1648-1660

Somatostatin and its analogues are known to have modulatory effects on immune response and their anti-proliferative, anti-angiogenic, and analgesic properties make them attractive candidates for a therapeutic use in immune-mediated diseases, such as rheumatoid arthritis. Here, we demonstrate the ability of the somatostatin analogue octreotide to inhibit interleukin-15 and to increase interleukin-10...

article

⁶⁸Ga‐somatostatin analogue PET‐CT: Analysis of costs and benefits in a public hospital setting

Tatiana Segard, Laurence MJA Morandeau, Elizabeth A Geelhoed, Roslyn J Francis

Journal of Medical Imaging and Radiation Oncology > 62 > 1 > 57 - 63

Introduction Between 2009 and 2012, ⁶⁸Ga‐somatostatin analogue PET‐CT progressively replaced ¹¹¹In‐octreotide scintigraphy for imaging neuroendocrine tumours in WA public hospitals due to published literature demonstrating improved diagnostic accuracy and increased availability. Despite significantly improved sensitivity and specificity, ⁶⁸Ga‐somatostatin analogue PET is currently unfunded in Australia...

article

Management of neuroendocrine tumors of unknown primary

Krystallenia Alexandraki, Anna Angelousi, Georgios Boutzios, Georgios Kyriakopoulos, more

Reviews in Endocrine and Metabolic Disorders > 2017 > 18 > 4 > 423-431

Neuroendocrine neoplams (NENs) are mostly relatively indolent malignancies but a significant number have metastatic disease at diagnosis mainly to the liver. Although in the majority of such cases the primary origin of the tumor can be identified, in approximately 11–22% no primary tumor is found and such cases are designated as NENs of unknown primary origin (UPO). This has significant therapeutic...

article

Diabetic ketoacidosis in acromegaly; a rare complication precipitated by corticosteroid use

Jeremy Weiss, Anna J. Wood, Jeffrey D. Zajac, Mathis Grossmann, more

Diabetes Research and Clinical Practice > 2017 > 134 > C > 29-37

Diabetic ketoacidosis has been described in the literature as a rare possible initial presentation of acromegaly before a diagnosis of acromegaly is eventually made. Indeed, diabetic ketoacidosis is a recognised complication of acromegaly. There are a number of factors that can predispose patients with acromegaly to diabetes as well as to diabetic ketoacidosis. These include high levels of growth...

article

Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts

C. Fottner, M. M. Weber

Der Onkologe > 2018 > 24 > 2 > 124-132

Publication date

Last 3 years (3)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Content availability

Available (144)
None (3)

Publication type

article (140)
book (7)

INFONA - science communication portal

Advanced search

Advanced search in people

Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome

Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series

The effects of somatostatin analogues on glycaemia in the treatment of neuroendocrine tumours

Resistance to first‐generation somatostatin receptor ligands does not impair the results of gamma knife radiosurgery in acromegaly

The Binding Ability of a Bicyclic Somatostatin Analogue Towards Cu(II) Ions

Management of portal hypertension and ascites in polycystic liver disease

Phäochromozytom und Paragangliom

Production and characterization of no-carrier-added ¹⁶¹Tb as an alternative to the clinically-applied ¹⁷⁷Lu for radionuclide therapy

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

Mixed neuroendocrine-non-neuroendocrine carcinoma of gallbladder: case report

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

My burning issues in neuroendocrine tumours (NET)

Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts

Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE)

Anti-inflammatory Effect of Somatostatin Analogue Octreotide on Rheumatoid Arthritis Synoviocytes

⁶⁸Ga‐somatostatin analogue PET‐CT: Analysis of costs and benefits in a public hospital setting

Management of neuroendocrine tumors of unknown primary

Diabetic ketoacidosis in acromegaly; a rare complication precipitated by corticosteroid use

Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts

Filter options

Publication date

Content availability

Publication type

Publication language

Keywords

Data set

INFONA - science communication portal

Advanced search

Advanced search in people

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication type

Publication language

Keywords

Data set

Reporting an error / abuse

Sending the report failed

Accessibility options